One Biosciences
Pre-clinicalTraditional bulk sequencing flattens complexity. We resolve it cell by cell. Using FFPE or frozen samples, our proprietary platform delivers high-quality single-cell maps and clinician-ready reports in less than two weeks. Backed by AI, validated across multiple tumor types and designed for real-world use, we are making single-cell data clinically usable.
Private Company
Total funding raised: $33.5M
About
Traditional bulk sequencing flattens complexity. We resolve it cell by cell. Using FFPE or frozen samples, our proprietary platform delivers high-quality single-cell maps and clinician-ready reports in less than two weeks. Backed by AI, validated across multiple tumor types and designed for real-world use, we are making single-cell data clinically usable.